Teva comments on Lovenox’s patent infringement lawsuit

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) commented today on the patent infringement lawsuit filed by Momenta Pharmaceuticals, Inc. and Sandoz Inc.

Teva received a copy of the complaint which claims that the manufacture of its generic Lovenox® (enoxaparin sodium) injection, which is still under active review at U.S. Food and Drug Administration, has infringed Momenta's U.S. Patent Nos. 7,575,886 (the "'886 patent") and 7,790,466 (the "'466 patent"), and will infringe those patents once it is officially approved and marketed in the United States. Teva's version of generic Lovenox, which is manufactured and tested outside of the U.S., does not infringe either of these patents. Teva believes that this lawsuit is without merit, and Teva intends to seek reimbursement for all legal fees in fighting these baseless allegations.